More on Triple-Negative Breast Cancer and BRCA1 Mutations: This Time from Greece

A Greek study provides further evidence that we must seriously consider testing for BRCA1 mutations in all triple-negative breast cancer patients under the age of 50 regardless of family history.

Abraxas: A New Hereditary Breast Cancer Gene

If you have a compelling family history of breast cancer that is not explained by a BRCA1 or BRCA2 gene mutation, another gene – Abraxas – has been added to the list of possible explanations.

New Evidence Supports BRCA1 Testing for All Women with Triple-Negative Breast Cancer Diagnosed Before Age 50

If you were diagnosed with triple-negative breast cancer before age 50, your chance of having a BRCA1 mutation is likely ~20%

Other Cancers Seen in Families with RAD51D Mutations

Two days ago we discussed a recent study by Dr. Nazneen Rahman and colleagues which clearly demonstrated that inherited mutations in a gene called RAD51D result in a substantial elevation in risk for ovarian cancer. This elevation in risk was seen in some families in which other cancer types were seen in the family tree. So, does this mean that the other cancer types in these families are also due to the RAD51D mutations?

Family History of Cancer Changes Over Time: Why You Need to Keep Your Primary Care Doctor Updated

If you are interested in cancer prevention, you may know that for common cancers family history is one of the most important and useful tools that we have to identify people at elevated risk (who are likely to benefit most from more intensive screening and/or preventative measures). Despite this fact, discussion of family history often [...]

New Financial Assistance Program for Young Women with BRCA1 and BRCA2 Mutations Needing Help Paying for Screening Breast MRI

In a previous post we mentioned a Christina Applegate appearance on Oprah to discuss both learning that she (Ms. Applegate) had Hereditary Breast and Ovarian Cancer risk due to a BRCA1 mutation and the aftermath. Since then, The Christina Applegate Foundation has worked to promote awareness of the importance of breast MRI screening for high-risk women. However, one key impediment for some women is the cost of MRI. Now, Right Action for Women is doing something to address this problem.

More on the Woman Who Filed an EEOC Complaint Claiming She Was Fired Over a Genetic Test Revealing a BRCA2 Mutation

The internet is abuzz with all kinds of information related to the case that we discussed yesterday here inovolving a Connecticut woman, Pamela Fink, who has filed a complaint with the EEOC and others alleging genetic discrimination under GINA (Genetic Information Nondiscrimination Act) . She states that her former employer, MXenergy, fired her because of a genetic test that revealed that she carried a mutation in the BRCA2 gene, which confers very high lifetime risks of breast and ovarian cancer.
Video is beginning to emerge (thanks to Nature News for pointing us in this direction) with more information about the case.

Myriad Genetics Has Raised The Price for BRCA1 and BRCA2 Testing: North of $4,000 Now

The Yale Cancer Genetic Counseling blog notes that on April 1, Myriad reportedly raised the full price for full sequencing and rearrangement testing of the BRCA1 and BRCA2 genes to $4,040 (from $3,770).

Woman Files Complaint Claiming She Was Fired Over Positive BRCA2 Test for Hereditary Breast and Ovarian Cancer

In one of the first complaints filed related to the Genetic Insurance Nondiscrimination Act, a Connecticut woman has filed complaints with the U.S. Equal Opportunity Commission and the Connecticut Commission on Human Rights and Opportunities. According to the Boston Herald, Pamela Fink, 39, of Fairfield, Connecticut, alleges that her employer, MXenergy fired her after she disclosed to them that she had a mutation in the BRCA2 gene (which confers hereditary breast and ovarian cancer susceptibility).

Myriad Breast Cancer Gene Patents and the Courts: Upcoming Genetic Alliance Webinar

We’ve mentioned the court case involving the Myriad breast cancer gene patents several times here at Cancer and Your Genes. Recently, we’ve discussed the rather surprising summary judgment decision invalidating some of Myriad Genetics’ patents on the BRCA1 and BRCA2 genes. This is just the opening salvo in a fight that may make it all the way to the Supreme Court.